Nutex Health (NASDAQ:NUTX) Director Scott Saunders Sells 203 Shares

Key Points

• Director Scott Saunders sold 203 Nutex Health shares at an average price of $214.25, generating $43,492.75 and reducing his direct ownership by 33.67% to 400 shares.
• NUTX traded at $208.79, near its 52-week high of $224.28. The company reported quarterly EPS of $9.38, exceeding analyst expectations of $4.95, while revenue came in slightly below estimates.
• Analyst sentiment remains broadly positive, with an average “Buy” rating and a $317.50 price target; institutional investors own 5.32% of the company after several firms initiated or increased positions.

Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) Director Scott Saunders sold 203 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $214.25, for a total value of $43,492.75. Following the sale, the director directly owned 400 shares in the company, valued at approximately $85,700. This trade represents a 33.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Nutex Health Price Performance

NUTX stock traded down $5.53 during midday trading on Friday, reaching $208.79. The company had a trading volume of 246,698 shares, compared to its average volume of 170,645. Nutex Health Inc. has a 1-year low of $83.99 and a 1-year high of $224.28. The stock has a 50 day moving average price of $179.08 and a 200-day moving average price of $143.31. The company has a debt-to-equity ratio of 0.59, a current ratio of 5.00 and a quick ratio of 4.96. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of 8.20 and a beta of 0.28.

Nutex Health (NASDAQ:NUTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $9.38 EPS for the quarter, beating the consensus estimate of $4.95 by $4.43. The firm had revenue of $210.75 million for the quarter, compared to analyst estimates of $215.03 million. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%. Equities research analysts expect that Nutex Health Inc. will post 27.58 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. bought a new position in Nutex Health during the 2nd quarter worth $69,612,000. Winmill & CO. Inc. bought a new stake in shares of Nutex Health in the 2nd quarter valued at about $11,168,000. Empowered Funds LLC acquired a new stake in shares of Nutex Health in the second quarter valued at about $7,720,000. SG Americas Securities LLC increased its stake in shares of Nutex Health by 3,232.6% in the first quarter. SG Americas Securities LLC now owns 30,360 shares of the company's stock valued at $2,885,000 after buying an additional 29,449 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Nutex Health during the second quarter worth about $3,956,000. 5.32% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on NUTX. B. Riley Financial boosted their price objective on shares of Nutex Health from $290.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, September 4th. Zacks Research upgraded Nutex Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, August 24th. Weiss Ratings raised Nutex Health from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, July 28th. Wall Street Zen downgraded Nutex Health from a "buy" rating to a "hold" rating in a research report on Saturday, September 5th. Finally, B Riley reaffirmed a "buy" rating on shares of Nutex Health in a research note on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $317.50.

Nutex Health Company Profile

Nutex Health Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, outpatient facilities and physician practices. The company focuses on delivering emergency, inpatient and outpatient care through community-based healthcare facilities, including micro-hospitals designed to provide essential hospital services in convenient local settings.

Its services may include emergency medicine, primary care, specialty care, diagnostic testing, imaging, laboratory services and other ancillary healthcare offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.